GNF2133 - Moligand™,≥98% , CAS No.2561414-56-8

CAS: 2561414-56-8 Cat. No.: G646983 Molecular Weight: 434.53

GRADE & PURITY Moligand™, ≥98%

Synonyms

4-Ethyl-N-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl)pyridin-2-yl)piperazine-1-carboxamide

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Overview

In Vivo

GNF2133 (30 mg/kg; p.o.) shows good oral absorption with oral bioavailability of 22.3%.

GNF2133 (30 mg/kg; p.o.; once a day for 5 days) shows the ability to proliferate β-cells in vivo.

GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion in RIP-DTA mice.

IC50 & Target

DYRK1,DYRK1A(0.0062 μM (IC50)),GSK3β(>50 μM (IC50))

Specifications

Synonyms

4-Ethyl-N-(4-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2, 3-c]pyridin-3-yl)pyridin-2-yl)piperazine-1-carboxamide

Specifications & Purity

Moligand™, ≥98%

Biochemical and Physiological Mechanisms

GNF2133 is a potent and selective DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capa

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

INHIBITOR

Purity

≥98%

Names and Identifiers

• Molecular Weight: 434.53

Chemical and Physical Properties

• Solubility: DMSO : 4 mg/mL (9.21 mM; ultrasonic and warming and heat to 60°C)